Our antibody database is primarily focused on protein-coding genes. Although they form only 1% of the total human genome, these important genes account for 85% of the mutations that lead to disease.
DNA sequencing (defining the sequence of the 4 base amino acids within the DNA strand) and then using antibodiesspecific to those sequences, is a vital part of disease research. Sanger sequencing is the standard for doing this. However, in 2007 a next generation (or next gen) sequencing technique was devised. Lauded as the biggest advancement in genomics since microarray technology, it has radically improved diagnostic research.
Sanger sequencing focuses on one gene or gene area at a time, producing long reads of 500 bases or more. By contrast, next-gen sequencing produces short reads of around 25 bases. However, hundreds or even thousands of reads can be produced from many areas of the genome at once. Multiplicity overcomes the error problems arising from short base sequences.
Immunoperoxidase of monoclonal antibody to SLC26A3
While the Sanger method is ideal for accurate “fine tuning” of single long amino acid chains, next-generation DNA sequencing allows selective sequencing of complete genes or coding regions (called whole exome coding). With a high specificity and sensitivity for heterozygous and homozygous variants, and a 95% capture rate of targeted coding sequences, it is ideal where antibodies are used for diagnostic purposes.
In 2009, Lifton, et al. applied next-gen DNA sequencing to identify congenital chloride diarrhoea in a patient originally suspected of suffering from Bartter syndrome, a renal salt-wasting disease. Whole exome sequencing revealed a mutation in the SLC26A3 protein – known to be expressed in CCD. We at Novus Biologicals have both partial recombinant protein and antibody preparations for SLC26A3 in our antibody catalog.
Novus Biologicals offers many SLC26A3 reagents for your research needs including:
